- Press Release Distribution

Synthetic peptide could reduce vascular problems associated with COVID-ARDS

Synthetic peptide could reduce vascular problems associated with COVID-ARDS
( AUGUSTA, Ga. (Oct. 4, 2022) – A synthetic peptide developed by researchers at the Medical College of Georgia could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19.

In severe cases, COVID-19 is associated with the syndrome, which happens when fluid builds up in the tiny, elastic air sacs in the lungs, keeping them from filling with enough air and keeping oxygen from reaching the bloodstream. “These are the people who get the sickest from the virus,” says Rudolf Lucas, PhD, vascular biologist in the Vascular Biology Center at the Medical College of Georgia. “It is a pathology with a very bad prognosis. Many of these patients must go on a ventilator and a significant percentage of them succumb.”

Researchers have long-known that COVID-ARDS is accompanied by a cytokine storm, when an over-aggressive immune system releases too many of these signaling proteins — which in healthy amounts help stimulate the immune system fight the infection — into the blood stream, which can eventually lead to multi-system organ failure. This cytokine storm can also occur in non-COVID ARDS. Since both severe COVID and non-COVID ARDS have a comparable mortality, Lucas and his team are working to delineate how the former differs from the latter and to identify novel therapeutic avenues.

“In agreement with recent findings by others, we think that what could represent the main difference is that SARS-CoV2-induced ARDS has a much higher vasculopathy, so much higher damage to the vasculature, as compared to non-COVID ARDS,” he explains. “This prompted us, and others, to look for factors specific to SARS-CoV-2 that make the endothelium that lines the blood vessels in the body so dysfunctional.”

When looking at endothelial cells body-wide, researchers have actually reported finding very little virus. What has been found, however, is that levels of the virus’ spike protein, which it uses to bind to receptors throughout the body, are higher in the serum of people with the more severe cases and can be detected even months after clearing most of the infection.
“So, we started looking into whether the receptor binding domain of the spike protein does something to the endothelial cells in the lungs,” Lucas says. “We found that the spike protein — specifically the subunit which contains the receptor binding site — makes endothelial cells dysfunctional.”

Essentially, he explains, the spike protein binds to a receptor — specifically human ACE2, which normally plays a role in protecting cell barriers. The virally induced shedding or downregulation of this receptor can cause the endothelium to start producing more angiotensin 2, eventually leading to more oxidative stress in the endothelium. “That destroys barriers and induces capillary leaks. On top of that this can induce tissue factor production in the endothelium, which can lead to micro-thrombi, or tiny clots that are typically found in mass in people who die of COVID-19. Now, we want to know if the spike protein somehow sensitizes the endothelium, leading to dysfunction, and how to counteract that.”

Lucas and his research team have been working for years on a synthetic peptide, called the TIP peptide (known as  Solnatide, AP301 in clinical trials) that has already shown promise in protecting kidneys from nephritis and preventing severe pneumonia. It essentially works by binding to a subunit of the epithelial sodium channel, called ENaC alpha, which is mainly expressed in the epithelium, like alveolar epithelium in the lungs, but also in the microvascular endothelium in capillaries. Their peptide has been shown to play an important role in keeping barrier function intact, especially in the presence of bacterial toxins.

Now they’re looking toward these severe cases of COVID-related ARDS, to see if they can use the peptide to prevent the dysfunction induced by the spike protein of the virus, Lucas and his colleagues report in the journal Frontiers in Immunology.

“The reason we are particularly interested in looking at ENaC in this context is that we know the spike protein in SARS-CoV-2 has to be cleaved between its two subunits in order for it to be able to bind to human ACE2,” Lucas says. “That cleavage is done by an enzyme called furin, which cleaves the protein in a sequence of eight amino acids. We already knew that in mammals, only one other protein has an identical cleavage sequence – ENaC alpha, where it is needed to mature the channel. Another mechanism through which the spike protein can impair ENaC is by inducing a protein called protein kinase C (PKC), which also impairs the function of the channel.”

In collaboration with Douglas Eaton, PhD, a physiologist from Emory University and a member of the Center for Cystic Fibrosis and Airways Disease Research at Children’s Healthcare of Atlanta, the team found that the TIP peptide, which binds to the alpha subunit of ENaC, can overcome the inhibitory effect of the spike protein on sodium uptake by the epithelial sodium channel.

“Importantly, the TIP peptide can actually reduce oxidative stress induced by the spike protein and restore human ACE2 surface expression in capillaries,” Lucas says. “We still don’t know exactly how the spike protein induces endothelial dysfunction,” but it does not seem to be extreme enough by itself to cause such vasculopathy.

Exploring further, the researchers believed the answer would come in understanding why patients who have both COVID and pneumococcal pneumonia have a mortality rate seven times higher than people with pneumonia alone. Using a similar model, they pretreated transgenic mice expressing human ACE2, generated by Lin Gan, PhD, director of MCG’s Transgenic & Genome Editing Core, with the spike protein and then infected them with Streptococcus pneumoniae. They found a much higher capillary leak as compared to mice which were only infected with pneumococci or mice which were only treated with the spike protein.

“Our findings show that with the combination of SARS-CoV-2 and pneumococcal pneumonia, there is a high increase in tissue factor production and in microthrombi, and all of that was inhibited when the mice were treated with the TIP peptide,” Lucas said. “This confirms our original hypothesis that the spike protein will sensitize the endothelium to become dysfunctional, but this will mainly only happen when there is a second insult.”
While COVID numbers have mostly waned, these findings could have implications in long COVID, which is known to be linked to endothelial dysfunction and increased oxidative stress. The research team has shown that treatment with the TIP peptide, even after spike protein delivery, reduces oxidative stress. “That could imply that regardless of the onset of symptoms, it is still having an effect when it is delivered,” he says. “That is something I would definitely like to look a bit more into.”

The TIP peptide is currently in phase 2 clinical trials in patients with COVID- and non-COVID ARDS in Austria and Germany, organized by the company APEPTICO. It also was approved for compassionate use treatment of severe COVID patients in Italy and Austria.

Read the study.


[Attachments] See images for this press release:
Synthetic peptide could reduce vascular problems associated with COVID-ARDS


Cardiology compensation and production remain relatively stable year-over-year

MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2023 Cardiovascular Provider Compensation and Production Survey Report that includes data from the largest number of providers since its debut. The report features a foreword from MedAxiom President and CEO Jerry Blackwell, MD, MBA, FACC, on the consistency of year-over-year data from 2021 to 2022, the importance of a robust pool of data to form the foundation of the report, and the application of data as a strategic planning tool.  2023 Report Highlights:   Compensation and production ...

Optimizing continuous-variable functions with quantum annealing

Optimizing continuous-variable functions with quantum annealing
Quantum annealing (QA) is a cutting-edge algorithm that leverages the unique properties of quantum computing to tackle complex combinatorial optimization problems (a class of mathematical problems dealing with discrete-variable functions). Quantum computers use the rules of quantum physics to solve such problems potentially faster than classical computers. In essence, they can explore multiple solutions to a problem simultaneously, giving them a significant speed advantage for certain tasks over classical computers. In particular, QA harnesses the phenomenon of “quantum ...

City of Hope opens first U.S. multicenter clinical trial for robotic single-port mastectomies for breast cancer patients

LOS ANGELES — City of Hope, one of the largest cancer research and treatment organizations in the United States, is opening a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies. The minimally invasive procedure, which preserves the nipple and leaves only a small hidden scar on the side of the body, could potentially lead to significant improvements for breast surgery. “City of Hope is once again taking the lead in investigating innovations, treatments and therapies that are making big leaps forward for patients with cancer. We’re participating ...

Emerging drug discovery ecosystems in Virginia

Emerging drug discovery ecosystems in Virginia
Oak Brook, IL – A Special Issue of SLAS Discovery, Emerging Drug Discovery Ecosystems, is new for September. Volume 28, Issue 6 features three perspectives, one original research article and one protocol that align with the Virginia Drug Discovery Consortium (VaDDC) and its efforts to enhance and promote drug discovery and development in the Commonwealth of Virginia. Perspective An acute respiratory distress syndrome drug development collaboration stimulated by the Virginia Drug Discovery Consortium This ...

Socioeconomic status and power outages

Socioeconomic status and power outages
Communities with more socioeconomic vulnerability experience longer-duration power outages than more advantaged communities, according to a study. Research has shown that environmental disasters hit economically and socially vulnerable communities hardest. Scott Ganz and colleagues assessed the unequal impacts caused by the procedures electric utilities follow to restore power to customers after extreme-weather related outages. Using data from eight Atlantic hurricanes that made landfall between January 2017 and October 2020, which knocked out power for a total of over 15 million customers in 588 counties in the Southeast, the authors find ...

Broad Clinical Labs established to expand clinical services

The Genomics Platform at the Broad Institute of MIT and Harvard has been one of the world’s leading academic genome sequencing centers since the days of the Human Genome Project. For the last decade, these services have included clinical sequencing and other molecular assays through its wholly-owned subsidiary, the Clinical Research Sequencing Platform. Now renamed Broad Clinical Labs (BCL), the lab is poised to further accelerate the power of ’omics technologies in clinical research, screening, and diagnostics. BCL supports large-scale projects for which results need to be generated under a clinical quality system, such as analyses for clinical trials, biobank profiling, ...

Bioengineering breakthrough increases DNA detection sensitivity by 100 times

Bioengineering breakthrough increases DNA detection sensitivity by 100 times
UMass Amherst researchers have pushed forward the boundaries of biomedical engineering one hundredfold with a new method for DNA detection with unprecedented sensitivity. “DNA detection is in the center of bioengineering,” says Jinglei Ping, lead author of the paper that appeared in Proceedings of the National Academy of Sciences. Ping is an assistant professor of mechanical and industrial engineering, an adjunct assistant professor in biomedical engineering and affiliated with the Center for Personalized Health Monitoring of the Institute for Applied Life Sciences. “Everyone ...

Type 2 diabetes diagnosis at age 30 can reduce life expectancy by up to 14 years

An individual diagnosed with type 2 diabetes at age 30 years could see their life expectancy fall by as much as 14 years, an international team of researchers has warned. Even people who do not develop the condition until later in life – with a diagnosis at age 50 years – could see their life expectancy fall by up to six years, an analysis of data from 19 high-income countries found. The researchers say the findings, published in The Lancet Diabetes & Endocrinology, highlight the urgent need to ...

New $81million NIH grant will help U.S. answer urgent need for better dementia care

Watching a loved one suffer the slow decline of dementia is hard enough. But trying to find care for them that’s high-quality, safe, available and affordable is nearly as difficult, as millions of American families have found out the hard way in recent years. That lack of options stems from a combination of workforce shortages, payment policies and a lack of consistency in dementia care delivery and regulation, according to experts from the University of Michigan and the University of California, San Francisco and their colleagues. Now, fueled by new five-year funding expected to total $81 million from the NIH’s National Institute on Aging or ...

Humans inherit artificial intelligence biases

New research by the psychologists Lucía Vicente and Helena Matute from Deusto University in Bilbao, Spain, provides evidence that people can inherit artificial intelligence biases (systematic errors in AI outputs) in their decisions. The astonishing results achieved by artificial intelligence systems, which can, for example, hold a conversation as a human does, have given this technology an image of high reliability. More and more professional fields are implementing AI-based tools to support the decision-making of specialists to minimise errors in their decisions. However, this technology is not without risks due to biases in AI results. ...


ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

New Sylvester cancer study provides insight into underlying gene mutations in myelodysplastic syndromes

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

Mindfulness could help women with opioid use disorder better control drug urges

TTUHSC’s ARPA-H membership will spur innovation, improve access for West Texas patients

Global annual finance flows of $7 trillion fueling climate, biodiversity, and land degradation crises

Tracing how the infant brain responds to touch with near-infrared spectroscopy

These are the world's most effective charities

When is an aurora not an aurora?

Advisory panel issues field-defining recommendations for US government investments in particle physics research

Doctors discover many patients at UNC’s Inflammatory Bowel Disease Clinic screen positive for malnutrition

BNL: Advisory panel issues field-defining recommendations for U.S. government investments in particle physics research

International collaboration uses faculty member’s research on ancient Roman migration, seeks to understand Balkan genomic history

USF Health Heart Institute doctors are upbeat about cardiac regeneration

AI-driven breakthroughs in cells study: SFU-UBC collaboration introduces "MCS-detect" for advancements in super-resolution microscopy

Advisory panel issues field-defining recommendations for investments in particle physics research

$3.8 million NIH grant to fund Southwest Center on Resilience for Climate Change and Health

What happens when the brain loses a hub? 

Study reveals Zika’s shape-shifting machinery—and a possible vulnerability

RIT leading STEM co-mentoring network

Genetic mutations that promote reproduction tend to shorten human lifespan, study shows

CAMH develops potential new drug treatment for multiple sclerosis

Polyethylene waste could be a thing of the past

A dynamic picture of how we respond to high or low oxygen levels

University of Toronto researchers discover new lipid nanoparticle that shows muscle-specific mRNA delivery, reduces off-target effects.

Evolving insights in blood-based liquid biopsies for prostate cancer interrogation

Finding the most heat-resistant substances ever made

[] Synthetic peptide could reduce vascular problems associated with COVID-ARDS